vs
Side-by-side financial comparison of Rimini Street, Inc. (RMNI) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Rimini Street, Inc. is the larger business by last-quarter revenue ($105.5M vs $70.6M, roughly 1.5× Viridian Therapeutics, Inc.\DE). Rimini Street, Inc. runs the higher net margin — 1.3% vs -49.0%, a 50.3% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 1.2%).
Rimini Street, Inc. is a global provider of independent third-party support services for enterprise software products including Oracle and SAP platforms. It serves clients across multiple industries worldwide, delivering cost-effective support, maintenance, and consulting solutions that help businesses cut operational expenses while ensuring software performance and security.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
RMNI vs VRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $105.5M | $70.6M |
| Net Profit | $1.4M | $-34.6M |
| Gross Margin | 59.0% | — |
| Operating Margin | 4.6% | -56.7% |
| Net Margin | 1.3% | -49.0% |
| Revenue YoY | 1.2% | 81958.1% |
| Net Profit YoY | -59.4% | 54.9% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $105.5M | — | ||
| Q4 25 | $109.8M | — | ||
| Q3 25 | $103.4M | $70.6M | ||
| Q2 25 | $104.1M | — | ||
| Q1 25 | $104.2M | — | ||
| Q4 24 | $114.2M | — | ||
| Q3 24 | $104.7M | — | ||
| Q2 24 | $103.1M | — |
| Q1 26 | $1.4M | — | ||
| Q4 25 | $724.0K | — | ||
| Q3 25 | $2.8M | $-34.6M | ||
| Q2 25 | $30.3M | — | ||
| Q1 25 | $3.4M | — | ||
| Q4 24 | $6.7M | — | ||
| Q3 24 | $-43.1M | — | ||
| Q2 24 | $-1.1M | — |
| Q1 26 | 59.0% | — | ||
| Q4 25 | 60.4% | — | ||
| Q3 25 | 59.9% | — | ||
| Q2 25 | 60.4% | — | ||
| Q1 25 | 61.0% | — | ||
| Q4 24 | 63.7% | — | ||
| Q3 24 | 60.7% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | 4.6% | — | ||
| Q4 25 | 4.5% | — | ||
| Q3 25 | 4.2% | -56.7% | ||
| Q2 25 | 39.6% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 13.0% | — | ||
| Q3 24 | -47.4% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | 1.3% | — | ||
| Q4 25 | 0.7% | — | ||
| Q3 25 | 2.7% | -49.0% | ||
| Q2 25 | 29.1% | — | ||
| Q1 25 | 3.2% | — | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | -41.2% | — | ||
| Q2 24 | -1.1% | — |
| Q1 26 | $0.01 | — | ||
| Q4 25 | $0.00 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.32 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $-0.47 | — | ||
| Q2 24 | $-0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $132.2M | $490.9M |
| Total DebtLower is stronger | $56.4M | — |
| Stockholders' EquityBook value | — | $503.0M |
| Total Assets | $397.1M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $132.2M | — | ||
| Q4 25 | $120.0M | — | ||
| Q3 25 | $108.7M | $490.9M | ||
| Q2 25 | $101.3M | — | ||
| Q1 25 | $122.6M | — | ||
| Q4 24 | $88.8M | — | ||
| Q3 24 | $119.5M | — | ||
| Q2 24 | $134.2M | — |
| Q1 26 | $56.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $-27.0M | — | ||
| Q3 25 | $-27.3M | $503.0M | ||
| Q2 25 | $-29.0M | — | ||
| Q1 25 | $-63.7M | — | ||
| Q4 24 | $-69.4M | — | ||
| Q3 24 | $-76.8M | — | ||
| Q2 24 | $-36.1M | — |
| Q1 26 | $397.1M | — | ||
| Q4 25 | $423.1M | — | ||
| Q3 25 | $352.9M | $577.1M | ||
| Q2 25 | $397.5M | — | ||
| Q1 25 | $343.0M | — | ||
| Q4 24 | $369.1M | — | ||
| Q3 24 | $343.8M | — | ||
| Q2 24 | $367.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $19.6M | — | ||
| Q3 25 | $24.7M | $-84.6M | ||
| Q2 25 | $-17.8M | — | ||
| Q1 25 | $33.7M | — | ||
| Q4 24 | $-37.7M | — | ||
| Q3 24 | $-18.5M | — | ||
| Q2 24 | $6.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $18.9M | — | ||
| Q3 25 | $23.5M | $-84.7M | ||
| Q2 25 | $-19.5M | — | ||
| Q1 25 | $32.8M | — | ||
| Q4 24 | $-38.4M | — | ||
| Q3 24 | $-19.2M | — | ||
| Q2 24 | $5.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | 17.2% | — | ||
| Q3 25 | 22.7% | -120.1% | ||
| Q2 25 | -18.8% | — | ||
| Q1 25 | 31.5% | — | ||
| Q4 24 | -33.6% | — | ||
| Q3 24 | -18.3% | — | ||
| Q2 24 | 5.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.2% | 0.2% | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 27.02× | — | ||
| Q3 25 | 8.94× | — | ||
| Q2 25 | -0.59× | — | ||
| Q1 25 | 10.06× | — | ||
| Q4 24 | -5.66× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
